REPROCELL
@reprocell.bsky.social
Better translating discoveries into therapies. Follow for updates about products, services, and industry news.
What if 𝗔𝗜 could design 𝗯𝗲𝘁𝘁𝗲𝗿 𝗴𝗲𝗻𝗲 𝗲𝗱𝗶𝘁𝗼𝗿𝘀 than what evolution gave us? 𝗢𝗽𝗲𝗻𝗖𝗥𝗜𝗦𝗣𝗥-𝟭 - the first AI-designed genome editing enzyme - might be exactly that.
In our 𝗹𝗮𝘁𝗲𝘀𝘁 𝗯𝗹𝗼𝗴, we explain:
✔What OpenCRISPR-1 is & how it was created
✔Why developers should care
👉Read the 𝗯𝗹𝗼𝗴: hubs.li/Q03YjfQp0
In our 𝗹𝗮𝘁𝗲𝘀𝘁 𝗯𝗹𝗼𝗴, we explain:
✔What OpenCRISPR-1 is & how it was created
✔Why developers should care
👉Read the 𝗯𝗹𝗼𝗴: hubs.li/Q03YjfQp0
December 17, 2025 at 10:50 AM
What if 𝗔𝗜 could design 𝗯𝗲𝘁𝘁𝗲𝗿 𝗴𝗲𝗻𝗲 𝗲𝗱𝗶𝘁𝗼𝗿𝘀 than what evolution gave us? 𝗢𝗽𝗲𝗻𝗖𝗥𝗜𝗦𝗣𝗥-𝟭 - the first AI-designed genome editing enzyme - might be exactly that.
In our 𝗹𝗮𝘁𝗲𝘀𝘁 𝗯𝗹𝗼𝗴, we explain:
✔What OpenCRISPR-1 is & how it was created
✔Why developers should care
👉Read the 𝗯𝗹𝗼𝗴: hubs.li/Q03YjfQp0
In our 𝗹𝗮𝘁𝗲𝘀𝘁 𝗯𝗹𝗼𝗴, we explain:
✔What OpenCRISPR-1 is & how it was created
✔Why developers should care
👉Read the 𝗯𝗹𝗼𝗴: hubs.li/Q03YjfQp0
🎉Congratulations to 𝗼𝘂𝗿 𝗽𝗮𝗿𝘁𝗻𝗲𝗿 𝗣𝗿𝗼𝗳𝗹𝘂𝗲𝗻𝘁 on their successful $𝟭𝟬𝟲𝗠 𝗿𝗮𝗶𝘀𝗲! Their latest funding round, led by Altimeter Capital and Bezos Expeditions - marks a major milestone in advancing 𝗔𝗜-𝗱𝗿𝗶𝘃𝗲𝗻 𝗽𝗿𝗼𝘁𝗲𝗶𝗻 𝗱𝗲𝘀𝗶𝗴𝗻 𝗳𝗼𝗿 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀, agriculture, and beyond.
Find out more: hubs.li/Q03XR4ht0
Find out more: hubs.li/Q03XR4ht0
Profluent bags $106m for AI-driven protein design tech
The Series B aims to fuel expansion into therapeutics, agriculture, and biomanufacturing applications.
hubs.li
December 12, 2025 at 10:16 AM
🎉Congratulations to 𝗼𝘂𝗿 𝗽𝗮𝗿𝘁𝗻𝗲𝗿 𝗣𝗿𝗼𝗳𝗹𝘂𝗲𝗻𝘁 on their successful $𝟭𝟬𝟲𝗠 𝗿𝗮𝗶𝘀𝗲! Their latest funding round, led by Altimeter Capital and Bezos Expeditions - marks a major milestone in advancing 𝗔𝗜-𝗱𝗿𝗶𝘃𝗲𝗻 𝗽𝗿𝗼𝘁𝗲𝗶𝗻 𝗱𝗲𝘀𝗶𝗴𝗻 𝗳𝗼𝗿 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀, agriculture, and beyond.
Find out more: hubs.li/Q03XR4ht0
Find out more: hubs.li/Q03XR4ht0
Check out our GMP iPSC MCB services:
- GMP iPSC MCB Services US: hubs.li/Q03X0fc-0
- GMP iPSC MCB Services Europe: hubs.li/Q03X0bv60
- GMP iPSC MCB Services US: hubs.li/Q03X0fc-0
- GMP iPSC MCB Services Europe: hubs.li/Q03X0bv60
December 10, 2025 at 1:58 PM
Check out our GMP iPSC MCB services:
- GMP iPSC MCB Services US: hubs.li/Q03X0fc-0
- GMP iPSC MCB Services Europe: hubs.li/Q03X0bv60
- GMP iPSC MCB Services US: hubs.li/Q03X0fc-0
- GMP iPSC MCB Services Europe: hubs.li/Q03X0bv60
If you’re exploring 𝐚𝐥𝐥𝐨𝐠𝐞𝐧𝐞𝐢𝐜 𝐢𝐏𝐒𝐂-𝐝𝐞𝐫𝐢𝐯𝐞𝐝 𝐭𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬 and planning 𝐢𝐧𝐝𝐮𝐬𝐭𝐫𝐲-𝐬𝐜𝐚𝐥𝐞 𝐜𝐞𝐥𝐥 𝐦𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠, our latest article, featured in BioInformant, gives a clear look at how REPROCELL can support your program with a regulatory-ready GMP iPSC MCB.
👉 Check out the article: hubs.li/Q03X0dK70
👉 Check out the article: hubs.li/Q03X0dK70
GMP Manufacturing of iPSC Master Cell Banks for Allogeneic Therapies at REPROCELL: A Cost-Optimized Approach | BioInformant
Are you advancing an iPSC therapy program and planning for clinical-scale manufacturing of GMP Master Cell Banks (MCBs)? REPROCELL provides industry-standard, GMP-compliant iPSC MCB manufacturing serv...
hubs.li
December 5, 2025 at 11:17 AM
If you’re exploring 𝐚𝐥𝐥𝐨𝐠𝐞𝐧𝐞𝐢𝐜 𝐢𝐏𝐒𝐂-𝐝𝐞𝐫𝐢𝐯𝐞𝐝 𝐭𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬 and planning 𝐢𝐧𝐝𝐮𝐬𝐭𝐫𝐲-𝐬𝐜𝐚𝐥𝐞 𝐜𝐞𝐥𝐥 𝐦𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠, our latest article, featured in BioInformant, gives a clear look at how REPROCELL can support your program with a regulatory-ready GMP iPSC MCB.
👉 Check out the article: hubs.li/Q03X0dK70
👉 Check out the article: hubs.li/Q03X0dK70
REPROCELL isn’t just another iPSC vendor. We’re an 𝗲𝗻𝗱-𝘁𝗼-𝗲𝗻𝗱 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗶𝗣𝗦𝗖 𝗽𝗮𝗿𝘁𝗻𝗲𝗿 covering the entire journey in-house: donor sourcing, reprogramming, GMP MCB and gene-editing support for clinical programs.
𝗢𝗻𝗲 𝗽𝗮𝗿𝘁𝗻𝗲𝗿, 𝗼𝗻𝗲 𝘀𝘂𝗽𝗽𝗹𝘆 𝗰𝗵𝗮𝗶𝗻, 𝘇𝗲𝗿𝗼 𝗵𝗮𝗻𝗱𝗼𝗳𝗳𝘀.
Learn more: hubs.li/Q03WBDmb0
𝗢𝗻𝗲 𝗽𝗮𝗿𝘁𝗻𝗲𝗿, 𝗼𝗻𝗲 𝘀𝘂𝗽𝗽𝗹𝘆 𝗰𝗵𝗮𝗶𝗻, 𝘇𝗲𝗿𝗼 𝗵𝗮𝗻𝗱𝗼𝗳𝗳𝘀.
Learn more: hubs.li/Q03WBDmb0
December 3, 2025 at 10:53 AM
REPROCELL isn’t just another iPSC vendor. We’re an 𝗲𝗻𝗱-𝘁𝗼-𝗲𝗻𝗱 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗶𝗣𝗦𝗖 𝗽𝗮𝗿𝘁𝗻𝗲𝗿 covering the entire journey in-house: donor sourcing, reprogramming, GMP MCB and gene-editing support for clinical programs.
𝗢𝗻𝗲 𝗽𝗮𝗿𝘁𝗻𝗲𝗿, 𝗼𝗻𝗲 𝘀𝘂𝗽𝗽𝗹𝘆 𝗰𝗵𝗮𝗶𝗻, 𝘇𝗲𝗿𝗼 𝗵𝗮𝗻𝗱𝗼𝗳𝗳𝘀.
Learn more: hubs.li/Q03WBDmb0
𝗢𝗻𝗲 𝗽𝗮𝗿𝘁𝗻𝗲𝗿, 𝗼𝗻𝗲 𝘀𝘂𝗽𝗽𝗹𝘆 𝗰𝗵𝗮𝗶𝗻, 𝘇𝗲𝗿𝗼 𝗵𝗮𝗻𝗱𝗼𝗳𝗳𝘀.
Learn more: hubs.li/Q03WBDmb0
Curious how to scale your iPSC-based therapy from bench to clinic? Check out the images 👇 to explore how REPROCELL delivers GMP-compliant iPSC MCB manufacturing - from donor sourcing and footprint-free reprogramming to full regulatory-ready cell banks under FDA/EMA/PMDA standards.
November 28, 2025 at 10:45 AM
Curious how to scale your iPSC-based therapy from bench to clinic? Check out the images 👇 to explore how REPROCELL delivers GMP-compliant iPSC MCB manufacturing - from donor sourcing and footprint-free reprogramming to full regulatory-ready cell banks under FDA/EMA/PMDA standards.
The recording of our recent webinar - “Innovative Cell Technologies to Bioengineer Human Tissues In Vitro for Use in R&D and Modelling Human Disease” with Prof. Stefan Przyborski, is now live!
View the recording here 👉 hubs.li/Q03VW9Bz0
Explore our Alvetex® webpage: hubs.li/Q03VWjkS0
View the recording here 👉 hubs.li/Q03VW9Bz0
Explore our Alvetex® webpage: hubs.li/Q03VWjkS0
November 26, 2025 at 11:12 AM
The recording of our recent webinar - “Innovative Cell Technologies to Bioengineer Human Tissues In Vitro for Use in R&D and Modelling Human Disease” with Prof. Stefan Przyborski, is now live!
View the recording here 👉 hubs.li/Q03VW9Bz0
Explore our Alvetex® webpage: hubs.li/Q03VWjkS0
View the recording here 👉 hubs.li/Q03VW9Bz0
Explore our Alvetex® webpage: hubs.li/Q03VWjkS0
Our custom research iPSC service supports research-grade stem cell projects, spanning the full workflow from human donor sourcing to differentiated derivatives.
Find out more: hubs.li/Q03Vm6GR0
Find out more: hubs.li/Q03Vm6GR0
November 21, 2025 at 11:45 AM
Our custom research iPSC service supports research-grade stem cell projects, spanning the full workflow from human donor sourcing to differentiated derivatives.
Find out more: hubs.li/Q03Vm6GR0
Find out more: hubs.li/Q03Vm6GR0
In our latest blog, REPROCELL dives into how 𝗲𝘅𝗼𝘀𝗼𝗺𝗲𝘀 are emerging as 𝗰𝗲𝗹𝗹-𝗳𝗿𝗲𝗲 𝗮𝗹𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝘃𝗲𝘀 to conventional cell therapies.
Read more on our blog: hubs.li/Q03TXHKp0
Check out REPROCELL's iPSC-derived Exosomes: hubs.li/Q03TXJ8j0
Read more on our blog: hubs.li/Q03TXHKp0
Check out REPROCELL's iPSC-derived Exosomes: hubs.li/Q03TXJ8j0
November 19, 2025 at 11:24 AM
In our latest blog, REPROCELL dives into how 𝗲𝘅𝗼𝘀𝗼𝗺𝗲𝘀 are emerging as 𝗰𝗲𝗹𝗹-𝗳𝗿𝗲𝗲 𝗮𝗹𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝘃𝗲𝘀 to conventional cell therapies.
Read more on our blog: hubs.li/Q03TXHKp0
Check out REPROCELL's iPSC-derived Exosomes: hubs.li/Q03TXJ8j0
Read more on our blog: hubs.li/Q03TXHKp0
Check out REPROCELL's iPSC-derived Exosomes: hubs.li/Q03TXJ8j0
We’re excited to launch highly purified iPSC-derived exosomes for pre-clinical & advanced research, made at our Japan GMP facility. Derived from StemRNA™ clinical-grade iPSCs, available in liquid & lyophilized forms, ideal for anti-aging & collagen production studies.
Learn more: hubs.li/Q03TbmM50
Learn more: hubs.li/Q03TbmM50
November 14, 2025 at 10:15 AM
We’re excited to launch highly purified iPSC-derived exosomes for pre-clinical & advanced research, made at our Japan GMP facility. Derived from StemRNA™ clinical-grade iPSCs, available in liquid & lyophilized forms, ideal for anti-aging & collagen production studies.
Learn more: hubs.li/Q03TbmM50
Learn more: hubs.li/Q03TbmM50
Advancing an iPSC therapy program? We offer GMP iPSC MCB manufacturing in the EU (via Histocell) and the US (REPROCELL USA).
• EU (Histocell): hubs.li/Q03SMwJz0
• US (REPROCELL USA): hubs.li/Q03SMtVL0
Ready to discuss your project requirements? Submit an inquiry or email us: 𝗶𝗻𝗳𝗼-𝗲𝗺𝗲𝗮@𝗿𝗲𝗽𝗿𝗼𝗰𝗲𝗹𝗹.𝗰𝗼𝗺
• EU (Histocell): hubs.li/Q03SMwJz0
• US (REPROCELL USA): hubs.li/Q03SMtVL0
Ready to discuss your project requirements? Submit an inquiry or email us: 𝗶𝗻𝗳𝗼-𝗲𝗺𝗲𝗮@𝗿𝗲𝗽𝗿𝗼𝗰𝗲𝗹𝗹.𝗰𝗼𝗺
November 12, 2025 at 11:43 AM
Advancing an iPSC therapy program? We offer GMP iPSC MCB manufacturing in the EU (via Histocell) and the US (REPROCELL USA).
• EU (Histocell): hubs.li/Q03SMwJz0
• US (REPROCELL USA): hubs.li/Q03SMtVL0
Ready to discuss your project requirements? Submit an inquiry or email us: 𝗶𝗻𝗳𝗼-𝗲𝗺𝗲𝗮@𝗿𝗲𝗽𝗿𝗼𝗰𝗲𝗹𝗹.𝗰𝗼𝗺
• EU (Histocell): hubs.li/Q03SMwJz0
• US (REPROCELL USA): hubs.li/Q03SMtVL0
Ready to discuss your project requirements? Submit an inquiry or email us: 𝗶𝗻𝗳𝗼-𝗲𝗺𝗲𝗮@𝗿𝗲𝗽𝗿𝗼𝗰𝗲𝗹𝗹.𝗰𝗼𝗺
Join our webinar on 🗓️6 Nov 2025 with Prof. Stefan Przyborski: learn how Alvetex® scaffolds can help you build layered, human-relevant tissue models.
🕛 EMEA 12:00 UK / 13:00 CET
🕛 US 12:00 EST / 09:00 PST
👉Seats are filling fast, you can save your spot here: hubs.li/Q03P57jb0
🕛 EMEA 12:00 UK / 13:00 CET
🕛 US 12:00 EST / 09:00 PST
👉Seats are filling fast, you can save your spot here: hubs.li/Q03P57jb0
November 3, 2025 at 10:06 AM
Join our webinar on 🗓️6 Nov 2025 with Prof. Stefan Przyborski: learn how Alvetex® scaffolds can help you build layered, human-relevant tissue models.
🕛 EMEA 12:00 UK / 13:00 CET
🕛 US 12:00 EST / 09:00 PST
👉Seats are filling fast, you can save your spot here: hubs.li/Q03P57jb0
🕛 EMEA 12:00 UK / 13:00 CET
🕛 US 12:00 EST / 09:00 PST
👉Seats are filling fast, you can save your spot here: hubs.li/Q03P57jb0
REPROCELL is thrilled to have attended the 2025 Cell & Gene Therapy Symposium – Mid-Atlantic in Washington D.C., where researchers, clinicians and industry united to advance cell & gene therapies from discovery to patient care.
October 31, 2025 at 10:35 AM
REPROCELL is thrilled to have attended the 2025 Cell & Gene Therapy Symposium – Mid-Atlantic in Washington D.C., where researchers, clinicians and industry united to advance cell & gene therapies from discovery to patient care.
Join us on 𝟲 𝗡𝗼𝘃𝗲𝗺𝗯𝗲𝗿 2025 for a webinar on 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗖𝗲𝗹𝗹 𝗧𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝗶𝗲𝘀 𝘁𝗼 𝗕𝗶𝗼𝗲𝗻𝗴𝗶𝗻𝗲𝗲𝗿 𝗛𝘂𝗺𝗮𝗻 𝗧𝗶𝘀𝘀𝘂𝗲𝘀 𝙄𝙣 𝙑𝙞𝙩𝙧𝙤 𝗳𝗼𝗿 𝗨𝘀𝗲 𝗶𝗻 𝗥&𝗗 𝗮𝗻𝗱 𝗠𝗼𝗱𝗲𝗹𝗹𝗶𝗻𝗴 𝗛𝘂𝗺𝗮𝗻 𝗗𝗶𝘀𝗲𝗮𝘀𝗲 with 𝗣𝗿𝗼𝗳. 𝗦𝘁𝗲𝗳𝗮𝗻 𝗣𝗿𝘇𝘆𝗯𝗼𝗿𝘀𝗸𝗶.
🕛 EMEA Session: 12:00 UK / 13:00 CET
🕛 US Session: 12:00 EST / 9:00 PST
🔗𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 here: hubs.li/Q03Q0-hk0
🕛 EMEA Session: 12:00 UK / 13:00 CET
🕛 US Session: 12:00 EST / 9:00 PST
🔗𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 here: hubs.li/Q03Q0-hk0
October 30, 2025 at 10:18 AM
Join us on 𝟲 𝗡𝗼𝘃𝗲𝗺𝗯𝗲𝗿 2025 for a webinar on 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗖𝗲𝗹𝗹 𝗧𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝗶𝗲𝘀 𝘁𝗼 𝗕𝗶𝗼𝗲𝗻𝗴𝗶𝗻𝗲𝗲𝗿 𝗛𝘂𝗺𝗮𝗻 𝗧𝗶𝘀𝘀𝘂𝗲𝘀 𝙄𝙣 𝙑𝙞𝙩𝙧𝙤 𝗳𝗼𝗿 𝗨𝘀𝗲 𝗶𝗻 𝗥&𝗗 𝗮𝗻𝗱 𝗠𝗼𝗱𝗲𝗹𝗹𝗶𝗻𝗴 𝗛𝘂𝗺𝗮𝗻 𝗗𝗶𝘀𝗲𝗮𝘀𝗲 with 𝗣𝗿𝗼𝗳. 𝗦𝘁𝗲𝗳𝗮𝗻 𝗣𝗿𝘇𝘆𝗯𝗼𝗿𝘀𝗸𝗶.
🕛 EMEA Session: 12:00 UK / 13:00 CET
🕛 US Session: 12:00 EST / 9:00 PST
🔗𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 here: hubs.li/Q03Q0-hk0
🕛 EMEA Session: 12:00 UK / 13:00 CET
🕛 US Session: 12:00 EST / 9:00 PST
🔗𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 here: hubs.li/Q03Q0-hk0
We're excited to add a 23-year-old, Caucasian male (A⁺ blood type) donor line to our StemRNA™ clinical iPSC portfolio. Multiple iPSC clones from this donor are now ready for testing, the perfect foundation for advancing your cell therapy development.
Explore more: hubs.li/Q03PSDPF0
Explore more: hubs.li/Q03PSDPF0
October 24, 2025 at 9:28 AM
We're excited to add a 23-year-old, Caucasian male (A⁺ blood type) donor line to our StemRNA™ clinical iPSC portfolio. Multiple iPSC clones from this donor are now ready for testing, the perfect foundation for advancing your cell therapy development.
Explore more: hubs.li/Q03PSDPF0
Explore more: hubs.li/Q03PSDPF0
Excited to share that thanks to the MSCRF Manufacturing Assistance grant, we’re building a full-scale GMP/CDMO facility (Maryland) for large-batch hiPSC-derived & MSC therapy manufacturing, turnkey services from banking and gene-editing to differentiation & production.
Read more: hubs.li/Q03PGxWh0
Read more: hubs.li/Q03PGxWh0
October 22, 2025 at 1:49 PM
Excited to share that thanks to the MSCRF Manufacturing Assistance grant, we’re building a full-scale GMP/CDMO facility (Maryland) for large-batch hiPSC-derived & MSC therapy manufacturing, turnkey services from banking and gene-editing to differentiation & production.
Read more: hubs.li/Q03PGxWh0
Read more: hubs.li/Q03PGxWh0
We're excited to announce that REPROCELL & Histocell have jointly achieved AEMPS GMP certification for the manufacturing of 𝗶𝗣𝗦𝗖 𝗠𝗮𝘀𝘁𝗲𝗿 & 𝗪𝗼𝗿𝗸𝗶𝗻𝗴 𝗖𝗲𝗹𝗹 𝗕𝗮𝗻𝗸𝘀 using REPROCELL’s 𝗦𝘁𝗲𝗺𝗥𝗡𝗔™ 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗶𝗣𝗦𝗖𝘀, produced at Histocell’s newly certified GMP facility in Spain.
Learn more: hubs.li/Q03PgkGb0
Learn more: hubs.li/Q03PgkGb0
October 20, 2025 at 9:35 AM
We're excited to announce that REPROCELL & Histocell have jointly achieved AEMPS GMP certification for the manufacturing of 𝗶𝗣𝗦𝗖 𝗠𝗮𝘀𝘁𝗲𝗿 & 𝗪𝗼𝗿𝗸𝗶𝗻𝗴 𝗖𝗲𝗹𝗹 𝗕𝗮𝗻𝗸𝘀 using REPROCELL’s 𝗦𝘁𝗲𝗺𝗥𝗡𝗔™ 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗶𝗣𝗦𝗖𝘀, produced at Histocell’s newly certified GMP facility in Spain.
Learn more: hubs.li/Q03PgkGb0
Learn more: hubs.li/Q03PgkGb0
In our recent webinar Dr Luana Ferrara showed how Qkine’s high-purity, animal-free growth factors & cytokines address reproducibility challenges in stem cell, organoid & disease models.
Couldn’t join us live? The 𝗳𝘂𝗹𝗹 𝘄𝗲𝗯𝗶𝗻𝗮𝗿 𝗿𝗲𝗰𝗼𝗿𝗱𝗶𝗻𝗴 is now online, on our 𝗬𝗼𝘂𝗧𝘂𝗯𝗲 channel → hubs.ly/Q03MVw-D0
Couldn’t join us live? The 𝗳𝘂𝗹𝗹 𝘄𝗲𝗯𝗶𝗻𝗮𝗿 𝗿𝗲𝗰𝗼𝗿𝗱𝗶𝗻𝗴 is now online, on our 𝗬𝗼𝘂𝗧𝘂𝗯𝗲 channel → hubs.ly/Q03MVw-D0
October 17, 2025 at 10:39 AM
In our recent webinar Dr Luana Ferrara showed how Qkine’s high-purity, animal-free growth factors & cytokines address reproducibility challenges in stem cell, organoid & disease models.
Couldn’t join us live? The 𝗳𝘂𝗹𝗹 𝘄𝗲𝗯𝗶𝗻𝗮𝗿 𝗿𝗲𝗰𝗼𝗿𝗱𝗶𝗻𝗴 is now online, on our 𝗬𝗼𝘂𝗧𝘂𝗯𝗲 channel → hubs.ly/Q03MVw-D0
Couldn’t join us live? The 𝗳𝘂𝗹𝗹 𝘄𝗲𝗯𝗶𝗻𝗮𝗿 𝗿𝗲𝗰𝗼𝗿𝗱𝗶𝗻𝗴 is now online, on our 𝗬𝗼𝘂𝗧𝘂𝗯𝗲 channel → hubs.ly/Q03MVw-D0
𝗥𝗲𝗽𝗿𝗼 𝗠𝗦𝗖𝟭𝟬 now include 𝗢𝗻𝗰𝗼𝗣𝗮𝗻𝗲𝗹 𝗴𝗲𝗻𝗼𝗺𝗶𝗰 𝗽𝗿𝗼𝗳𝗶𝗹𝗶𝗻𝗴 at every stage — from donor fibroblasts → iPSCs → iMSCs. Get assurance of chromosomal integrity via G-band karyotyping + NGS-based variant screening across 400+ cancer-related genes.
Check out Repro MSC10 here: www.reprocell.com/product-cata...
Check out Repro MSC10 here: www.reprocell.com/product-cata...
October 15, 2025 at 7:07 AM
𝗥𝗲𝗽𝗿𝗼 𝗠𝗦𝗖𝟭𝟬 now include 𝗢𝗻𝗰𝗼𝗣𝗮𝗻𝗲𝗹 𝗴𝗲𝗻𝗼𝗺𝗶𝗰 𝗽𝗿𝗼𝗳𝗶𝗹𝗶𝗻𝗴 at every stage — from donor fibroblasts → iPSCs → iMSCs. Get assurance of chromosomal integrity via G-band karyotyping + NGS-based variant screening across 400+ cancer-related genes.
Check out Repro MSC10 here: www.reprocell.com/product-cata...
Check out Repro MSC10 here: www.reprocell.com/product-cata...
Thrilled to see REPROCELL featured by @bioinformant.bsky.social.
From iPSCs, MSCs, and iMSCs, to MCB generation, clinical or research gene editing, we support your stem cell projects end-to-end.
From iPSCs, MSCs, and iMSCs, to MCB generation, clinical or research gene editing, we support your stem cell projects end-to-end.
Clinical #StemCell Services: REPROCELL's experts in cell therapy manufacturing will take you through all the stages of your regenerative medicine project
www.reprocell.com/clinical-ste...
www.reprocell.com/clinical-ste...
October 10, 2025 at 9:07 AM
Thrilled to see REPROCELL featured by @bioinformant.bsky.social.
From iPSCs, MSCs, and iMSCs, to MCB generation, clinical or research gene editing, we support your stem cell projects end-to-end.
From iPSCs, MSCs, and iMSCs, to MCB generation, clinical or research gene editing, we support your stem cell projects end-to-end.
𝗥𝗘𝗣𝗥𝗢𝗖𝗘𝗟𝗟 𝗨.𝗦.𝗔., 𝗜𝗻𝗰., has been awarded a 𝗠𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 𝗔𝘀𝘀𝗶𝘀𝘁𝗮𝗻𝗰𝗲 𝗴𝗿𝗮𝗻𝘁 from the 𝗠𝗮𝗿𝘆𝗹𝗮𝗻𝗱 𝗦𝘁𝗲𝗺 𝗖𝗲𝗹𝗹 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗙𝘂𝗻𝗱 (𝗠𝗦𝗖𝗥𝗙), supporting life-saving stem cell research. Thanks to MSCRF & TEDCO — exciting updates are ahead!
Find out more: www.tedcomd.com/news-events/...
Find out more: www.tedcomd.com/news-events/...
Maryland Stem Cell Research Fund Awards $4.7 million to Support Innovations in Stem Cell Research | TEDCO
The grants will drive research and development programs in regenerative medicine across Maryland
www.tedcomd.com
October 8, 2025 at 7:08 AM
𝗥𝗘𝗣𝗥𝗢𝗖𝗘𝗟𝗟 𝗨.𝗦.𝗔., 𝗜𝗻𝗰., has been awarded a 𝗠𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 𝗔𝘀𝘀𝗶𝘀𝘁𝗮𝗻𝗰𝗲 𝗴𝗿𝗮𝗻𝘁 from the 𝗠𝗮𝗿𝘆𝗹𝗮𝗻𝗱 𝗦𝘁𝗲𝗺 𝗖𝗲𝗹𝗹 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗙𝘂𝗻𝗱 (𝗠𝗦𝗖𝗥𝗙), supporting life-saving stem cell research. Thanks to MSCRF & TEDCO — exciting updates are ahead!
Find out more: www.tedcomd.com/news-events/...
Find out more: www.tedcomd.com/news-events/...
🔥Could iMSCs be the future of burn care? A new study shows that iMSCs derived from iPSCs significantly accelerate healing of full-thickness burns in pigs — pointing to their potential in regenerative medicine.
Study: hubs.li/Q03LTwgq0
Our iMSC products: hubs.li/Q03LTwc_0
Study: hubs.li/Q03LTwgq0
Our iMSC products: hubs.li/Q03LTwc_0
Human iPSCs-derived mesenchymal stem cells promote skin regeneration and burn wound healing - npj Regenerative Medicine
npj Regenerative Medicine - Human iPSCs-derived mesenchymal stem cells promote skin regeneration and burn wound healing
hubs.li
October 3, 2025 at 10:06 AM
🔥Could iMSCs be the future of burn care? A new study shows that iMSCs derived from iPSCs significantly accelerate healing of full-thickness burns in pigs — pointing to their potential in regenerative medicine.
Study: hubs.li/Q03LTwgq0
Our iMSC products: hubs.li/Q03LTwc_0
Study: hubs.li/Q03LTwgq0
Our iMSC products: hubs.li/Q03LTwc_0
REPROCELL now offers our gene-engineered 𝗵𝘆𝗽𝗼𝗶𝗺𝗺𝘂𝗻𝗲 𝗶𝗣𝗦𝗖𝘀 (𝗕𝟮𝗠 𝗼𝗿 𝗱𝘂𝗮𝗹 𝗕𝟮𝗠 + 𝗖𝗜𝗜𝗧𝗔 𝗸𝗻𝗼𝗰𝗸𝗼𝘂𝘁𝘀) in combination with the unmodified parental StemRNA™ iPSC line—a bundle ideal for robust experimental design.
👉 𝗢𝘂𝗿 𝗶𝗣𝗦𝗖𝘀 𝗮𝗿𝗲 𝗯𝘂𝗶𝗹𝘁 𝗳𝗼𝗿 𝘁𝗿𝗮𝗻𝘀𝗹𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲.
🌐 hubs.li/Q03GqzMM0
👉 𝗢𝘂𝗿 𝗶𝗣𝗦𝗖𝘀 𝗮𝗿𝗲 𝗯𝘂𝗶𝗹𝘁 𝗳𝗼𝗿 𝘁𝗿𝗮𝗻𝘀𝗹𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲.
🌐 hubs.li/Q03GqzMM0
StemEdit Hypoimmune iPSCs
Discover REPROCELL's StemEdit™ hypoimmune iPSC lines, enabling advanced immune research and clinical applications with high-quality genome editing technology and regulatory-compliant cell lines.
hubs.li
September 30, 2025 at 12:45 PM
REPROCELL now offers our gene-engineered 𝗵𝘆𝗽𝗼𝗶𝗺𝗺𝘂𝗻𝗲 𝗶𝗣𝗦𝗖𝘀 (𝗕𝟮𝗠 𝗼𝗿 𝗱𝘂𝗮𝗹 𝗕𝟮𝗠 + 𝗖𝗜𝗜𝗧𝗔 𝗸𝗻𝗼𝗰𝗸𝗼𝘂𝘁𝘀) in combination with the unmodified parental StemRNA™ iPSC line—a bundle ideal for robust experimental design.
👉 𝗢𝘂𝗿 𝗶𝗣𝗦𝗖𝘀 𝗮𝗿𝗲 𝗯𝘂𝗶𝗹𝘁 𝗳𝗼𝗿 𝘁𝗿𝗮𝗻𝘀𝗹𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲.
🌐 hubs.li/Q03GqzMM0
👉 𝗢𝘂𝗿 𝗶𝗣𝗦𝗖𝘀 𝗮𝗿𝗲 𝗯𝘂𝗶𝗹𝘁 𝗳𝗼𝗿 𝘁𝗿𝗮𝗻𝘀𝗹𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲.
🌐 hubs.li/Q03GqzMM0
What if the future of regenerative medicine is already here?
In the last two years, the FDA approved three stem cell therapies—Ryoncil, Omisirge, and Lyfgenia—which push boundaries in immune repair, recovery, and rare diseases.
Explore more: hubs.li/Q03GtPW90
In the last two years, the FDA approved three stem cell therapies—Ryoncil, Omisirge, and Lyfgenia—which push boundaries in immune repair, recovery, and rare diseases.
Explore more: hubs.li/Q03GtPW90
Current Landscape of FDA Stem Cell Approvals and Trials 2023-2025
Discover the latest advancements and FDA approvals in stem cell therapies, including iPSC and MSC treatments, reshaping the 2023-2025 clinical landscape.
hubs.li
September 3, 2025 at 2:42 PM
What if the future of regenerative medicine is already here?
In the last two years, the FDA approved three stem cell therapies—Ryoncil, Omisirge, and Lyfgenia—which push boundaries in immune repair, recovery, and rare diseases.
Explore more: hubs.li/Q03GtPW90
In the last two years, the FDA approved three stem cell therapies—Ryoncil, Omisirge, and Lyfgenia—which push boundaries in immune repair, recovery, and rare diseases.
Explore more: hubs.li/Q03GtPW90
GMP MCB Workflow — Part 2
Who? Our GMP stem cell team in Beltsville uses a closed system to produce iPSCs/iMSCs MCBs.
What? We collect ethically consented skin biopsies, use footprint-free StemRNA™ technology, and expand to GMP MCBs.
Why? Quality, speed, and scale for GMP MCBs.
Who? Our GMP stem cell team in Beltsville uses a closed system to produce iPSCs/iMSCs MCBs.
What? We collect ethically consented skin biopsies, use footprint-free StemRNA™ technology, and expand to GMP MCBs.
Why? Quality, speed, and scale for GMP MCBs.
September 1, 2025 at 1:34 PM
GMP MCB Workflow — Part 2
Who? Our GMP stem cell team in Beltsville uses a closed system to produce iPSCs/iMSCs MCBs.
What? We collect ethically consented skin biopsies, use footprint-free StemRNA™ technology, and expand to GMP MCBs.
Why? Quality, speed, and scale for GMP MCBs.
Who? Our GMP stem cell team in Beltsville uses a closed system to produce iPSCs/iMSCs MCBs.
What? We collect ethically consented skin biopsies, use footprint-free StemRNA™ technology, and expand to GMP MCBs.
Why? Quality, speed, and scale for GMP MCBs.